Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Audran

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Vaccine|April 9, 1999
MHC class I- and class II-restricted processing and presentation of microencapsulated antigensY Men, R Audran, C Thomasin, et al.
Parassitologia|March 4, 2000
Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase I clinical studiesM A Roggero, C Weilenmann, A Bonelo, et al.
European Journal of Immunology|July 13, 2001
A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategiesJ A López, C Weilenman, R Audran, et al.
Scientific Reports|June 4, 2024
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I studyR Audran, H Chtioui, A C Thierry, et al.
Infection and Immunity|September 30, 2009
Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165cS Olugbile, C Kulangara, G Bang, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Vaccine|April 9, 1999
MHC class I- and class II-restricted processing and presentation of microencapsulated antigensY Men, R Audran, C Thomasin, et al.
Parassitologia|March 4, 2000
Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase I clinical studiesM A Roggero, C Weilenmann, A Bonelo, et al.
European Journal of Immunology|July 13, 2001
A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategiesJ A López, C Weilenman, R Audran, et al.
Scientific Reports|June 4, 2024
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I studyR Audran, H Chtioui, A C Thierry, et al.
Infection and Immunity|September 30, 2009
Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165cS Olugbile, C Kulangara, G Bang, et al.
Pageof 4